Adiposs raises CHF 1.8 million to start clinical trials and product industrialization

10.01.2022 14:29, Isabelle Mitchell

Adiposs, the developer of a unique diagnostic product for the non-invasive early detection of body wasting cachexia, announced a CHF 1.8 million first closing of its pre-Series A round. The round was led by Privilège Ventures, a Swiss-based venture capital firm focused on seed and early-stage investments. Other investors include CR Ventures (CRV), Kick Foundation (Venture Kick), Fondation Genevoise pour l’Innovation Technologique (Fongit), a Singapore-based family office (Kingbridge), and a group of business angels. Adiposs was a Venture Kick winner and a Venture Leader Life Sciences in 2020 and one of the TOP 100 Swiss Startups in 2021. 

The investment round will be used to manufacture the first batch of ImageBAT, a first-in-class contrast agent for brown adipose tissue detection, as well as to perform the first-in-human clinical trial.

Lucian Wagner, GP of Privilège Ventures SA, commented that Privilège was particularly attracted to the team of Adiposs and its founders. “We tracked them for 18 months, ever since their first Venture Kick presentation. Having this kind of a perspective on the founders makes the investment decision considerably easier when the time comes.”

“The first equity financing round will allow us to achieve two crucial development milestones and become a clinical-stage company,” said Andrej Babic, CEO of Adiposs. Pierre Morgon, Chairman of the Board, added: “We are proud to be supported by an investor syndicate led by Privilège Ventures and investors from Switzerland, the US, France, and Singapore, consistent with the worldwide potential of ImageBAT.”


The Adiposs co-founders (from left to right): Nathalie Stransky von Heilkron (CTO), Andrej Babic (CEO), and Justyna Plewka (COO)


Source: Adiposs website